Overview

Study Using CP-461 to Treat Advanced Prostate Cancer

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether an investigational drug, CP-461, is safe and effective for the treatment of patients with prostate cancer and who have measurable disease.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Cell Pathways
OSI Pharmaceuticals